Analysts Offer Insights on Healthcare Companies: Esperion (NASDAQ: ESPR) and Kezar Life Sciences Inc (NASDAQ: KZR)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Esperion (ESPRResearch Report) and Kezar Life Sciences Inc (KZRResearch Report) with bullish sentiments.

Esperion (ESPR)

In a report released yesterday, Chris Shibutani from Cowen & Co. maintained a Buy rating on Esperion, with a price target of $85. The company’s shares closed yesterday at $50.09.

According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.4% and a 42.0% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $69.13 average price target, representing a 38.0% upside. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Kezar Life Sciences Inc (KZR)

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Kezar Life Sciences Inc. The company’s shares closed yesterday at $9.81, close to its 52-week low of $8.61.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 4.4% and a 46.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

The the analyst consensus on Kezar Life Sciences Inc is currently a Moderate Buy rating.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.